Scientific research innovation

R&d pipeline

Dorzagliatin

mGluR5

Scientific journal

Peer reviewed publication

产品

Huatangin ®

Investor relations

Investor information center

Corporate governance

Financial report

Announcements and circulars

Listing document

Investor presentation

Investor Relations contact information

Investor relations calendar

Strategic advisory board

Senior Scientific Advisory Board

About Huanling

> About Huanling

> Strategic advisory board

Strategic advisory board

Senior Scientific Advisory Board

Media center

Strategic advisory board

John J. Dr. Baldwin

Baldwin博士是一名杰出的科学家以及曾连续创业的企业家。He began his career at the Merck Research Laboratory，30 years at MSD，He has led the development of several new drugs including Trusopt® and Cosopt® for glaucoma，And in cardiovascular disease treatment drug Aggrastat®, AIDS treatment drug Crixivan®，And the peptic ulcer treatment drug Pepcid® played a key role in the development process。Baldwin博士是新药研发技术公司美国药典（PCOP）的创始人，并曾担任首席科学官。Ten years later, he founded Vitae Pharmaceuticals (VTAE), where he served as President and Chief Scientific Officer and applied computational and molecular simulation techniques to drug discovery。He is a co-founder and director of Wuxi AppTec (Shanghai) and a director of GlycoMimetics (GLYC)。Baldwin博士已经发表超过125篇学术论文以及大量的综述，曾在超过150场美国国内或国际会议上发表演讲。He holds more than 240 U.S. patents。Dr. Baldwin has received numerous awards, including the prestigious Hershberg Award for discoveries of medically active substances, the University of Minnesota Distinguished Achievement Award, and the University of Delaware Distinguished Achievement Award。他于2007年秋天举行的ACS大会上入选美国药物化学名人堂，He received the Philadelphia Section Award for Ingenious Contributions to Chemistry from the American Chemical Society in 2008。Dr. Baldwin holds a B.S. in Chemistry from the University of Delaware and a Ph.D. from the University of Minnesota。

James S. Dr. MacDonald

James MacDonald博士曾任职先灵葆雅研究所临床前研究部门的执行副总裁，并于2008年退休。During his 15-year tenure at Schering-Plough, Dr. MacDonald was primarily responsible for guiding new potentially therapeutic compounds from discovery to development, including all internal research and development as well as external introduction programs across all therapeutic areas。During his tenure, he has evaluated hundreds of compounds, dozens of which have entered clinical trials, some have been sold worldwide, and many are still in the pipeline。Based on his previous work experience at Merck, Dr. MacDonald is directly responsible for the Toxicology and Drug Metabolism departments。在此之前，MacDonald博士在默沙东研究实验室工作了17年，最终担任毒理学部门执行总监，并参与了许多目前已经上市的重磅药物的研发。Dr. MacDonald was a member of the HESI Board for 15 years and eventually served as its President。自2012年美国科学院无机砷领域国家研究委员会成立以来，MacDonald博士一直担任该机构委员。Dr. MacDonald holds a Ph.D. in toxicology from the University of Cincinnati and completed postdoctoral research at Vanderbilt University。2008年，MacDonald博士创立了ChrysalisPharmaConsulting公司并担任总裁。The company is focused on supporting the late-stage optimization of lead compounds, helping to advance new molecular entities from early-stage clinical trials to clinical validation, thereby facilitating the development of innovative drugs。In 2014, he co-founded Synergy Partners with Dr. Catherine Strader。As founders of the company, Dr. MacDonald and Dr. Strader have built a network of experienced professionals from all disciplines involved in the discovery and development of new treatments。The network works with small and medium-sized pharmaceutical companies to develop innovative medicines for unmet clinical needs。MacDonald's current areas of interest are understanding the mechanisms of toxicity and advancing the process of cancer risk assessment。

Bennett M. Dr. Shapiro

Bennett M. Dr. Shapiro currently works for PureTech Health plc (PRTC).L) Co-founder and non-executive Director of the Company and Chairman of VBL therapeutics, Ltd (VBLT)。From 1990 to 2003，He served as Executive Vice President of Merck Research Laboratories, where he initially led Merck's basic research worldwide，Responsible for all basic research and preclinical research work of Merck;therewith，He leads Merck's program introduction, licensing, and external research efforts，Responsible for Merck's partnerships with biomedical research institutions in academia and industry。During his time at Merck, Dr. Shapiro led the development and registration of approximately 25 drugs and vaccines。 Prior to joining Merck, Dr. Shapiro was Professor and Chair of the Department of Biochemistry at the University of Washington。He has published more than 120 papers on molecular regulation of cell behavior and biochemical events that integrate tandem cell activation behavior during fertilization。Shapiro博士于迪金森学院获得化学学士学位，托马斯•杰弗逊大学获得医学博士学位。After an internship at the University of Pennsylvania School of Medicine, he worked as a research associate at the National Institutes of Health and then as a visiting scholar at the Pasteur Institute in Paris, France。He then returned to the National Institutes of Health as head of the Cell Differentiation Division in the Laboratory of Biochemistry。He later joined the faculty of the University of Washington。Dr. Shapiro has been a visiting professor at the Guggenheim Institute of Japan and the University of Nice, and has served on several advisory and scientific evaluation committees。Shapiro博士是Momenta Pharmaceuticals公司、Vedanta Biosciences公司、Tal Medical公司、Karuna Pharma公司、Akili InteractiveLaboratories公司，and director of the non-profit Drugs for Neglected Diseases initiative (DNDi), the Mind and LifeInstitute, and the GarrisonInstitute。

Catherine D. Dr. Strader

Catherine Strader博士拥有超过30年的医药研发经验，涉及从分子靶点选择到临床试验验证等多个专业领域。As Executive Vice President and Chief Scientific Officer of Schering-Plough's Development Research division, Dr. Strader is responsible for strategic planning and execution of Schering-Plough's global small molecule and biologic medicines。同时，Dr. Strader and his team initiated many projects that are currently very popular in Merck's R&D pipeline，Including BACE inhibitors for the treatment of Alzheimer's disease，Zontivity® for cardiovascular disease treatment，同时，He has also been involved in the early development of projects including biologics for the treatment of inflammation and the hepatitis C drug Victrelis®。During his tenure at Merck, Dr. Strader was responsible for developing and executing the company's overall strategy for external R&D, enriching Merck's early-stage R&D pipeline by leveraging external innovation resources。She later served as early stage R&D Director for Merck East New Jersey's large R&D campuses, where she was responsible for advancing early stage R&D projects at those campuses。Strader博士近期联合创立了Synergy Partners，She works with her colleagues as a consultant to help biopharmaceutical companies and venture capital-backed companies build and maintain their R&D pipelines both strategically and executically, These include timely transition from early discovery to early development, appropriate risk prediction of the R&D pipeline portfolio, and efficient multi-party partnership design。Dr. Strader holds a B.S. in Chemistry from the University of Virginia, a Ph.D. in chemistry from the California Institute of Technology, and completed postdoctoral research in Lefkowicz's lab at Duke University。He has published more than 150 academic papers。

Copyright © 2024 Hualing Pharmaceutical Technology (Shanghai) Co., LTD. Internet Drug Information Service Qualification Certificate No. : (Shanghai) -Non-business -2022-0079
Shanghai ICP for 140366554 -1

Shanghai Public network Anbei 31011502013809 Privacy Statement Terms of use

搜索

How do we use Cookies

We use Cookies and other technologies (" cookies ") to improve our website。Except for Cookies, which are strictly necessary，We also want to use Cookies (1) to understand how our website is used and how it is executed，Such as cross-site data statistics，(2) To provide you with additional functions and personalized services，(3) Provide you with social media interaction，And (4) for targeting and marketing purposes。By clicking "Accept all", you consent to the use of all Cookies and the corresponding data processing, which may include your browser information and IP address, and to the disclosure of personal data to third parties, as detailed in the Cookies section of our Privacy Policy。For more information and ways to withdraw your consent, please see the Cookie Privacy Policy.。 Cookie Privacy Policy

拒绝

接受

Scientific R&D

Scientific research innovation

R&d pipeline

Dorzagliatin

mGluR5

Scientific journal

Peer reviewed publication

产品

Huatangin ®

Investor relations

Investor information center

Corporate governance

Financial report

Announcements and circulars

Listing document

Investor presentation

Investor Relations contact information

Investor relations calendar

Stock information

Media information

Company news

Video zone

About Huanling

Company profile

Development course

Management team

Business partner

Strategic advisory board

Senior Scientific Advisory Board

Media center

Seek men of merit

Corporate culture

Open a position

Contact us

About Huanling

Strategic advisory board